Teva Pharmaceutical Industries Limited’s (TEVA) Hold Rating Reiterated at Jefferies Group LLC

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating restated by Jefferies Group LLC in a report released on Tuesday.

The analysts wrote, “MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner.””

TEVA has been the subject of several other research reports. Vetr downgraded Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 target price for the company. in a research note on Monday, May 22nd. CIBC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Thursday, April 6th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Finally, Deutsche Bank AG lowered their price objective on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, May 12th. Fifteen research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $42.88.

Teva Pharmaceutical Industries Limited (TEVA) traded up 1.217% during midday trading on Tuesday, reaching $32.865. 2,366,152 shares of the company’s stock traded hands. The stock has a 50-day moving average of $31.54 and a 200 day moving average of $32.37. The company has a market cap of $33.39 billion, a P/E ratio of 421.346 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 52-week low of $27.60 and a 52-week high of $55.79.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The business had revenue of $5.63 billion during the quarter, compared to analysts’ expectations of $5.69 billion. During the same quarter in the prior year, the business posted $1.20 earnings per share. Teva Pharmaceutical Industries Limited’s revenue was up 17.0% compared to the same quarter last year. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.75 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited’s (TEVA) Hold Rating Reiterated at Jefferies Group LLC” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://transcriptdaily.com/2017/07/25/teva-pharmaceutical-industries-limiteds-teva-hold-rating-reiterated-at-jefferies-group-llc.html.

A number of large investors have recently added to or reduced their stakes in TEVA. Schulhoff & Co. Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock valued at $372,000 after buying an additional 1,004 shares in the last quarter. Heritage Investors Management Corp raised its stake in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock valued at $6,065,000 after buying an additional 28,135 shares in the last quarter. Bank Hapoalim BM raised its stake in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock valued at $375,000 after buying an additional 980 shares in the last quarter. M Holdings Securities Inc. acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter valued at about $491,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock valued at $165,461,000 after buying an additional 801,106 shares in the last quarter. 56.19% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply